國家衛生研究院 NHRI:Item 3990099045/15374
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 851504      Online Users : 846
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/15374


    Title: Hericium erinaceus mycelium reduces the motivation to self-administer ketamine in male rats
    Authors: Chen, HH;Lee, MY
    Contributors: Center for Neuropsychiatric Research
    Abstract: Introduction: Ketamine therapy is considered a safe and effective way to alleviate symptoms associated with psychiatric disorders, including depression and anxiety [1]. However, recreational ketamine use has become popular in recent years [2]. The abuse liability of ketamine use has caused concern. The present study examined whether Hericium erinaceus (HE) mycelium and its major component erinacine A could reduce the motivation for ketamine Methods: Male Sprague-Dawley rats were trained to respond to intravenous ketamine (0.5 mg/kg/infusion) self-administration or food pellets. The effects of oral administration of HE mycelium or erinacine A on the motivation for ketamine and food were assessed using breakpoint test under a progressive ratio (PR) paradigm. Results: HE mycelium, but not erinacine A, significantly reduced the breakpoint for ketamine. In addition, HE mycelium did not affect the breakpoint for food reinforcement, while erinacine A significantly reduced the breakpoint for food reinforcement. Conclusions: The results reveal that HE mycelium is capable of attenuating the reinforcing efficacy of ketamine, which is not attributable to erinacine A. These findings suggest that a HE mycelium supplementation might reduce the risk to abuse ketamine in patients under ketamine therapy.
    Date: 2023-07
    Relation: British Journal of Pharmacology. 2023 Jul;180(Suppl. 1):1034.
    Link to: https://doi.org/10.1111/bph.16112
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0007-1188&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:001043027400735
    Appears in Collections:[Hwei-Hisen Chen] Conference Papers/Meeting Abstract

    Files in This Item:

    File Description SizeFormat
    ISI001043027400735.pdf180KbAdobe PDF31View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback